137281-23-3
基本信息
N-[4-[2-(2-氨基-4,7-二氢-4-氧代-1H-吡咯并[2,3-d]嘧啶-5-基)乙基]苯甲酰基]-L-谷氨酸二钠盐
培美曲塞二钠盐
Pemetrexed99%
PeMetrexed-13C5
PeMetrexed-15C5
PEMETREXED ACID
Premetred disodium
PEFLOXACINMESYLATE
Pemetrexed Hydrate
Pemetrexed disodium
N-[4-[2-(2-Amino-4,7
PeMetrexed disodiuM INT-6
Pemetrexed - Labeled 15N,13C5
The sour sour of the United States
N-(4- 2-(2-AMino-4,7-Dihydro-4-oxo-1H-pyrrol...
N-[4-[2-(2-AMino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyriMidin-5-yl)ethyl]benzoyl]-L-glutaMic acid
(S)-2-(4-(2-(2-Amino-4-oxo-4,7-dihydro-1H-pyrrolo-[2,3-d]pyrimidin-5-yl)ethyl)benzamido)pentanedi
N-(4-[2-(2-Amino-4,7-Dihydro-4-oxo-1H-pyrrolo)[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-Gluamic Acid
L-Glutamic acid, N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-
(S)-2-(4-(2-(2-AMino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyriMidin-5-yl)ethyl)benzaMido)pentanedioic acid
(S)-2-(4-(2-(2-AMino-4-oxo-4,7-dihydro-3H-pyrrolo[2,3-d]pyriMidin-5-yl)ethyl)benzaMido)pentanedioic acid
(2R)-2-{[4-(2-{2-aMino-4-oxo-1H,4H,7H-pyrrolo[2,3-d]pyriMidin-5-yl}ethyl)phenyl]forMaMido}pentanedioic acid
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic acid disodium salt
N-[4-[2-(2-aMino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyriMidin-5-yl)ethyl]benzoyl]L-GlutaMic acid (PeMetrexed acid)
物理化学性质
| 外观 | 白色或者淡绿色粉末。 |
| 密度 | 1.59±0.1 g/cm3(Predicted) |
| 储存条件 | 2-8°C(protect from light) |
| 储存条件 | Keep in dark place,Sealed in dry,2-8°C |
| 溶解度 | 微溶于在甲醇中 |
| 酸度系数(pKa) | 3.58±0.10(Predicted) |
| 形态 | 粉末晶体 |
| 颜色 | 白色至蓝色 |
| Merck | 14,7077 |
| 主要应用 | pharmaceutical small molecule |
| InChIKey | WBXPDJSOTKVWSJ-ZDUSSCGKSA-N |
| SMILES | C(O)(=O)[C@H](CCC(O)=O)NC(=O)C1=CC=C(CCC2C3C(=O)NC(N)=NC=3NC=2)C=C1 |
| CAS 数据库 | 137281-23-3(CAS DataBase Reference) |
应用领域
安全数据
| 危险性符号(GHS) |  GHS07 |
| 警示词 | 警告 |
| 危险性描述 | H302-H315-H319-H332-H335 |
| 防范说明 | P261-P280-P305+P351+P338 |
| WGK Germany | WGK 3 |
| RTECS号 | LZ9950100 |
| 海关编码 | 2933.99.9701 |
| 存储类别 | 11 - Combustible Solids |
| 毒害物质数据 | 137281-23-3(Hazardous Substances Data) |
制备方法
![N-[4-[2-(2-氨基-4,7-二氢-4-氧代-1H-吡咯并[2,3-D]嘧啶-5-基)乙基]苯甲酰]-L-谷氨酸二乙酯对甲苯磺酸盐](/CAS/GIF/165049-28-5.gif)
165049-28-5
137281-23-3
以(S)-2-(4-(2-(2-氨基-4-氧代-4,7-二氢-3H-吡咯并[2,3-d]嘧啶-5-基)乙基)苯甲酰胺基)戊二酸二乙酯 4-甲基苯磺酸盐为原料合成培美曲塞二钠盐的一般步骤如下： 1. 培美曲塞二酸的制备（式2）： a. 在反应器中加入1L的1N NaOH水溶液，冷却至5-15℃。 b. 向冷却的NaOH溶液中缓慢加入143g实施例1中制备的式3化合物，保持温度在5-15℃。 c. 在5-15℃下搅拌反应混合物2小时，随后进行过滤（HPLC纯度：99.8%）。 d. 向滤液中加入2L EtOH，然后在5-15℃下缓慢滴加2N HCl水溶液，调节pH至3.0。 e. 将形成的结晶混合物在40-50℃下搅拌1小时，然后在40℃下过滤。 f. 用2L纯水洗涤过滤产物，接着用1L EtOH洗涤。 g. 将洗涤后的产物溶解于4L EtOH/纯水（1:1，v/v）中，在40-50℃下搅拌1小时。 h. 冷却至室温后过滤，用2L纯水洗涤，再用1L EtOH洗涤。 i. 将产物在40-45℃下真空干燥16小时，得到88g培美曲塞二酸，为白色固体（产率：95%，HPLC纯度：99.9%，个别杂质含量：未提及）。
参考文献：
[1] Patent: US2016/214987, 2016, A1. Location in patent: Paragraph 0081
[2] Patent: US2008/45711, 2008, A1. Location in patent: Page/Page column 11
培美曲塞二钠盐价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2026/09/15 | HY-10820R | 培美曲塞二钠盐 Pemetrexed (Standard) | 137281-23-3 | 5 mg | 400元 |
| 2026/09/15 | HY-10820R | 培美曲塞二钠盐 Pemetrexed (Standard) | 137281-23-3 | 10 mg | 600元 |
| 2026/09/15 | HY-10820 | 培美曲塞二钠盐 Pemetrexed | 137281-23-3 | 5 mg | 184元 |
常见问题列表
Ki: 1.3 nM (TS), 7.2 nM (DHFR), 65 nM (GARFT)
Pemetrexed (LY231514) disodium is a novel classical antifolate, the antitumor activity of which may result from simultaneous and multipie inhibition of several key folate-requiring enzymes via its polyglutamated metabolites. Pemetrexed (LY231514) is one of the best substrates that is known for the enzyme FPGS (K m =1.6 μM and V max /K m =621). It is likely that polyglutamation and the polyglutamated metabolites of LY231514 play profound roles in determining both the selectivity and the antitumor activity of this novel agent. Whereas LY23l5l4 only moderately inhibits TS (K i =340 nM, recombinant mouse), the pentaglutamate of LY23l5l4 is 100-fold more potent (K i =3.4 nM), making LY231514 one of the most potent folate-based TS inhibitors.
The group of mice treated with PC61 plus Pemetrexed demonstrates statistically longer survival than other groups. In a survival analysis, significantly better survival is observed in the group of mice treated with PC61 plus Pemetrexed compare with those treated with PC61 alone, rat IgG plus Pemetrexed, or no treatment.